Selected article for: "16S rrna gene and fecal microbiota"

Author: Gaibani, Paolo; D’Amico, Federica; Bartoletti, Michele; Lombardo, Donatella; Rampelli, Simone; Fornaro, Giacomo; Coladonato, Simona; Siniscalchi, Antonio; Re, Maria Carla; Viale, Pierluigi; Brigidi, Patrizia; Turroni, Silvia; Giannella, Maddalena
Title: The Gut Microbiota of Critically Ill Patients With COVID-19
  • Cord-id: el7sdd23
  • Document date: 2021_6_29
  • ID: el7sdd23
    Snippet: The SARS-CoV-2-associated COVID-19 pandemic has shaken the global healthcare system. Although the best-known symptoms are dry cough and pneumonia, viral RNA has been detected in the stool and about half of COVID-19 patients exhibit gastrointestinal upset. In this scenario, special attention is being paid to the possible role of the gut microbiota (GM). Fecal samples from 69 COVID-19 patients from three different hospitals of Bologna (Italy) were analyzed by 16S rRNA gene-based sequencing. The GM
    Document: The SARS-CoV-2-associated COVID-19 pandemic has shaken the global healthcare system. Although the best-known symptoms are dry cough and pneumonia, viral RNA has been detected in the stool and about half of COVID-19 patients exhibit gastrointestinal upset. In this scenario, special attention is being paid to the possible role of the gut microbiota (GM). Fecal samples from 69 COVID-19 patients from three different hospitals of Bologna (Italy) were analyzed by 16S rRNA gene-based sequencing. The GM profile was compared with the publicly available one of healthy age- and gender-matched Italians, as well as with that of other critically ill non-COVID-19 patients. The GM of COVID-19 patients appeared severely dysbiotic, with reduced diversity, loss of health-associated microorganisms and enrichment of potential pathogens, particularly Enterococcus. This genus was far overrepresented in patients developing bloodstream infections (BSI) and admitted to the intensive care unit, while almost absent in other critically ill non-COVID-19 patients. Interestingly, the percentage of patients with BSI due to Enterococcus spp. was significantly higher during the COVID-19 pandemic than in the previous 3 years. Monitoring the GM of critically ill COVID-19 patients could help clinical management, by predicting the onset of medical complications such as difficult-to-treat secondary infections.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and longitudinal study: 1, 2
    • abdominal pain and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • abdominal pain and low molecular weight treatment: 1, 2
    • abdominal pain vomiting and liver transplantation: 1, 2, 3
    • abdominal pain vomiting and low molecular weight: 1
    • abdominal pain vomiting nausea and liver transplantation: 1, 2
    • abdominal pain vomiting nausea diarrhea and liver transplantation: 1
    • absolute number and longitudinal study: 1
    • liver transplantation and longitudinal study: 1
    • liver transplantation follow and longitudinal study: 1
    • lmwh hydroxychloroquine and low molecular weight: 1, 2, 3
    • longitudinal study and low molecular weight: 1